EP1935416A2 - Utilisation de l'acide (Z)-2-cyano-3-hydroxy-but-2-enoïque-(4'-trifluorromethylphenyl)-amide pour traiter la sclérose en plaques - Google Patents

Utilisation de l'acide (Z)-2-cyano-3-hydroxy-but-2-enoïque-(4'-trifluorromethylphenyl)-amide pour traiter la sclérose en plaques Download PDF

Info

Publication number
EP1935416A2
EP1935416A2 EP08004647A EP08004647A EP1935416A2 EP 1935416 A2 EP1935416 A2 EP 1935416A2 EP 08004647 A EP08004647 A EP 08004647A EP 08004647 A EP08004647 A EP 08004647A EP 1935416 A2 EP1935416 A2 EP 1935416A2
Authority
EP
European Patent Office
Prior art keywords
multiple sclerosis
compound
disease
formula
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP08004647A
Other languages
German (de)
English (en)
Other versions
EP1935416A3 (fr
Inventor
designation of the inventor has not yet been filed The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26246599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1935416(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0123571.2A external-priority patent/GB0123571D0/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of EP1935416A2 publication Critical patent/EP1935416A2/fr
Publication of EP1935416A3 publication Critical patent/EP1935416A3/fr
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to methods of treating multiple sclerosis.
  • the present invention relates to the treatment of multiple sclerosis with (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide, commonly known as teriflunomide.
  • leflunomide 5-methylisoxazole-4-carboxylic -(4-trifluoromethyl)-anilide
  • Leflunomide was first disclosed generically in U.S. Patent 4,087,535, issued on May 2, 1978 and specifically in U.S. Patent 4,284,786, issued on August 18, 1981 , wherein it was disclosed that the compound could be used for the treatment of multiple sclerosis.
  • the aforementioned patents are both incorporated herein by reference.
  • MS Multiple sclerosis
  • MM Multiple sclerosis
  • the disease primarily affects young adults with a higher incidence in females. Symptoms of the disease include fatigue, numbness, tremor, tingling, dysesthesias, visual disturbances, dizziness, cognitive impairment, urologic dysfunction, decreased mobility, and depression.
  • Four types classify the clinical patterns of the disease: relapsing-remitting, secondary progressive, primary-progressive and progressive-relapsing ( S.L. Hauser and D.E. Goodkin, Multiple Sclerosis and Other Demyelinating Diseases in Harrison's Principles of Internal Medicine 14th Edition, vol. 2, Mc Graw-Hill, 1998, pp. 2409-2419 ).
  • MS myelin basic protein
  • T-cell proliferation and other cellular events such as activation of B cells and macrophages and secretion of cytokines accompanied by a breakdown of the blood-brain barrier can cause destruction of myelin and oligodendrocytes.
  • R.A. Adams, M.V. Victor and A.H. Ropper eds, Principles of Neurology, Mc Graw-Hill, New York, 1997, pp.903-921 Progressive MS (primary and secondary may be based on a nuerodegenerative process occurring with demyelination.
  • the present invention is a method of treating multiple sclerosis in patients by administering a compound of Formula I or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount to treat the disease.
  • the present invention also comprises a method of treating multiple sclerosis in patients by administering a combination of a compound of Formula I or a pharmaceutically acceptable salt thereof, with another compound known to be effective for the treatment of multiple sclerosis in therapeutically effective amounts to treat the disease.
  • step A commercially available cyanoacetic acid ethyl ester is reacted with commercially available 4-trifluoromethylaniline neat at elevated temperature to give cyanoacet-(4-trifluoromethyl)anilide.
  • step B the product from step A is dissolved in tetrahydrofuran and reacted with NaH in acetonitrile followed by reaction with acetyl chloride to produce the compound of Formula I.
  • One method of showing the utility of the present compound as a pharmaceutical that may be useful for the treatment of various conditions associated with MS is its ability to inhibit effects of experimental allergic encephalomyelitis in laboratory animals.
  • EAE Experimental allergic encephalomyelitis
  • a compound of Formula (I) can be administered in any form or mode which makes the compound bioavailable in therapeutically effective amounts, including orally, sublingually, buccally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, topically, and the like.
  • One skilled in the art of preparing formulations can determine the proper form and mode of administration depending upon the particular characteristics of the compound selected for the condition or disease to be treated, the stage of the disease, the condition of the patient and other relevant circumstances. For example, see Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990 ), incorporated herein by reference.
  • the compound of the present invention may be administered orally, for example, in the form of tablets, troches, capsules, elixirs, suspensions, solutions, syrups, wafers, chewing gums and the like and may contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and sweetening agents such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring.
  • binders such as microcrystalline cellulose, gum tragacanth or gelatin
  • excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like
  • lubricants such as
  • the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil.
  • a liquid carrier such as polyethylene glycol or a fatty oil.
  • Other dosage unit forms may contain other various materials, which modify the physical form of the dosage unit, for example, as coatings.
  • tablets or pills may be coated with sugar, shellac, or other enteric coating agents.
  • a syrup may contain, in addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the compound of Formula I of this invention may also be administered topically, and when done so the carrier may suitably comprise a solution, ointment or gel base.
  • the base for example, may comprise one or more of petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
  • the solutions or suspensions may also include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials.
  • the dosage range at which the compound of Formula I exhibits its ability to act therapeutically can vary depending upon its severity, the patient, the formulation, other underlying disease states that the patient is suffering from, and other medications that may be concurrently administered to the patient.
  • the compound of Formula I will exhibit their therapeutic activities at dosages of between about 0.001 mg/kg of patient body weight/day to about 100 mg/kg of patient body weight/day.
  • EAE Experimental allergic encephalomyelitis
  • the EAE rodent model is an appropriate tool for studying the inflammation of the brain and spinal cord observed in MS patients.
  • injection of whole spinal cord or spinal cord components such as myelin basic protein induces an autoimmune response based on the activation of T-lymphocytes.
  • Clinical disease typically becomes manifest around day 8-10 after inoculation, observed as a broad spectrum of behavioral anomalies ranging from mild gait disturbances and tail atony to complete paralysis and death. Weight loss typically occurs.
  • animals that survive spontaneous recovery occurs, accompanied by variable recovery of most motor function.
  • animals tested by the EAE model may experience a single (acute EAE) or several (chronic relapsing EAE) attacks.
  • treatment paradigms may be used: the drug or treatment of choice may be administered before immunization, during the nonsymptomatic period or during the clinical disease.
  • Antigen preparation (for approximately 720 animals)
EP08004647A 2001-04-05 2002-04-04 Utilisation de l'acide (Z)-2-cyano-3-hydroxy-but-2-enoïque-(4'-trifluorromethylphenyl)-amide pour traiter la sclérose en plaques Ceased EP1935416A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28168501P 2001-04-05 2001-04-05
GBGB0123571.2A GB0123571D0 (en) 2001-04-05 2001-10-02 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP02763962A EP1381356B1 (fr) 2001-04-05 2002-04-04 Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP02763962A Division EP1381356B1 (fr) 2001-04-05 2002-04-04 Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques

Publications (2)

Publication Number Publication Date
EP1935416A2 true EP1935416A2 (fr) 2008-06-25
EP1935416A3 EP1935416A3 (fr) 2008-10-22

Family

ID=26246599

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02763962A Expired - Lifetime EP1381356B1 (fr) 2001-04-05 2002-04-04 Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques
EP08004647A Ceased EP1935416A3 (fr) 2001-04-05 2002-04-04 Utilisation de l'acide (Z)-2-cyano-3-hydroxy-but-2-enoïque-(4'-trifluorromethylphenyl)-amide pour traiter la sclérose en plaques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP02763962A Expired - Lifetime EP1381356B1 (fr) 2001-04-05 2002-04-04 Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques

Country Status (15)

Country Link
EP (2) EP1381356B1 (fr)
AR (1) AR033459A1 (fr)
AT (1) ATE396719T1 (fr)
CA (1) CA2443285C (fr)
CY (1) CY2014004I2 (fr)
DE (1) DE60226855D1 (fr)
DK (1) DK1381356T3 (fr)
ES (1) ES2305287T3 (fr)
FR (1) FR14C0010I2 (fr)
LU (1) LU92366I2 (fr)
PA (1) PA8542901A1 (fr)
PT (1) PT1381356E (fr)
SI (1) SI1381356T1 (fr)
UY (1) UY27244A1 (fr)
WO (1) WO2002080897A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005907A1 (fr) * 2009-07-10 2011-01-13 Sanofi-Aventis U.S. Llc Utilisation de la combinaison de tériflunomide et d'interféron bêta pour le traitement de la sclérose en plaques
US20140256758A1 (en) * 2013-02-04 2014-09-11 Dietmar WEITZ Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293500A1 (en) 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
SG142305A1 (en) * 2004-10-19 2008-05-28 Aventis Pharma Inc Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
JP5021488B2 (ja) 2004-12-21 2012-09-05 メルク セローノ ソシエテ アノニム スルホニルアミノ環式誘導体及びその使用
DK1844032T3 (da) 2005-01-31 2011-10-24 Merck Serono Sa N-hydroxyamid-derivater og deres anvendelse
CA2616479A1 (fr) 2005-09-01 2007-03-08 Ares Trading S.A. Traitement de la nevrite optique
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2100881A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Dérivés d'acide pyrimidinyl- ou pyridinylaminobenzoïque
EP2135610A1 (fr) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combinaison comportant des inhibiteurs DHODH et de la méthotrexate
EP2230232A1 (fr) 2009-03-13 2010-09-22 Almirall, S.A. Sels adjuvants de trométhamine dotés de dérivés d'acide azabiphénylaminobenzoïque en tant qu'inhibiteurs de la DHOD
EP2239256A1 (fr) 2009-03-13 2010-10-13 Almirall, S.A. Sel de sodium de l'acide 5-cyclopropyl-2-{[2-(2,6-difluorophényl)pyrimidin-5-yl]amino}benzoïque en tant qu'inhibiteurs de la DHOD
EP2228367A1 (fr) 2009-03-13 2010-09-15 Almirall, S.A. Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH
MX336663B (es) 2009-09-18 2016-01-27 Sanofi Sa Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada.
EP2314577A1 (fr) 2009-10-16 2011-04-27 Almirall, S.A. Procédé de fabrication de l'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
WO2016189406A1 (fr) 2015-05-23 2016-12-01 Ftf Pharma Private Limited Composition pharmaceutique de tériflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087535A (en) 1975-06-05 1978-05-02 Hoechst Aktiengesellschaft 5-Methyl-isoxazole-4-carboxylic acid anilides
US4284786A (en) 1978-12-16 1981-08-18 Hoechst Aktiengesellschaft 5-Methylisoxazole-4-carboxylic-(4-trifluoromethyl)-anilide
US4965276A (en) 1985-09-27 1990-10-23 Hoechst Aktiengesellschaft Medicaments to combat chronic graft-versus-host diseases
US5459163A (en) 1985-09-27 1995-10-17 Hoechst Aktiengesellschaft Medicament to combat autoimmune diseases
US5504084A (en) 1993-03-31 1996-04-02 Hoechst Aktiengesellschaft Pharmaceutical for the treatment of skin disorders
US5990141A (en) 1994-01-07 1999-11-23 Sugen Inc. Treatment of platelet derived growth factor related disorders such as cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087535A (en) 1975-06-05 1978-05-02 Hoechst Aktiengesellschaft 5-Methyl-isoxazole-4-carboxylic acid anilides
US4284786A (en) 1978-12-16 1981-08-18 Hoechst Aktiengesellschaft 5-Methylisoxazole-4-carboxylic-(4-trifluoromethyl)-anilide
US4965276A (en) 1985-09-27 1990-10-23 Hoechst Aktiengesellschaft Medicaments to combat chronic graft-versus-host diseases
US5459163A (en) 1985-09-27 1995-10-17 Hoechst Aktiengesellschaft Medicament to combat autoimmune diseases
US5679709A (en) 1985-09-27 1997-10-21 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases
US5504084A (en) 1993-03-31 1996-04-02 Hoechst Aktiengesellschaft Pharmaceutical for the treatment of skin disorders
US5990141A (en) 1994-01-07 1999-11-23 Sugen Inc. Treatment of platelet derived growth factor related disorders such as cancers

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Principles of Neurology", 1997, MC GRAW-HILL, pages: 903 - 921
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
BARTLETT R. R. ET AL., AGENT ACTION, vol. 32, no. 1-2, 1991, pages 10 - 21
BOLTON, C., MULT. SDER., vol. 1, no. 3, 1995, pages 143 - 9
BROD S. A. ET AL., ANN NEUROL, vol. 47, 2000, pages 127 - 131
BRUNEAU J-M ET AL., BIOCHEM. J., vol. 36, 1998, pages 299 - 303
CHERWINSKI H. M. ET AL., J PHARMACOL. EXP. THER., vol. 272, 1995, pages 460 - 8
PRKASH A. ET AL., DRUGS, vol. 58, no. 6, 1999, pages 1137 - 66
S.L. HAUSER; D.E. GOODKIN: "Harrison's Principles of Internal Medicine", vol. 2, 1998, MC GRAW-HILL, article "Multiple Sclerosis and Other Demyelinating Diseases", pages: 2409 - 2419
TEITELBAUM D. ET AL., PROC NATL ACAD SCI USA, vol. 96, 1999, pages 3842 - 3847

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005907A1 (fr) * 2009-07-10 2011-01-13 Sanofi-Aventis U.S. Llc Utilisation de la combinaison de tériflunomide et d'interféron bêta pour le traitement de la sclérose en plaques
EP2277515A1 (fr) * 2009-07-10 2011-01-26 Sanofi-Aventis Utilisation d'une combinaison de teriflunomide et d'interféron bêta pour le traitement de la sclérose en plaques
US20140256758A1 (en) * 2013-02-04 2014-09-11 Dietmar WEITZ Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
US9186346B2 (en) * 2013-02-04 2015-11-17 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Also Published As

Publication number Publication date
ATE396719T1 (de) 2008-06-15
WO2002080897A1 (fr) 2002-10-17
DE60226855D1 (de) 2008-07-10
LU92366I2 (fr) 2014-03-31
PT1381356E (pt) 2008-07-24
FR14C0010I2 (fr) 2014-11-21
EP1381356A1 (fr) 2004-01-21
AR033459A1 (es) 2003-12-17
UY27244A1 (es) 2002-07-31
SI1381356T1 (sl) 2008-12-31
FR14C0010I1 (fr) 2014-03-14
PA8542901A1 (es) 2003-11-12
CA2443285C (fr) 2007-08-21
CY2014004I1 (el) 2015-12-09
EP1381356B1 (fr) 2008-05-28
EP1935416A3 (fr) 2008-10-22
DK1381356T3 (da) 2008-09-22
ES2305287T3 (es) 2008-11-01
CA2443285A1 (fr) 2002-10-17
CY2014004I2 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CA2443285C (fr) Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques
US6794410B2 (en) Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20070197643A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
WO1999027949A1 (fr) PROCEDES DE SUPPRESSION DES MODIFICATIONS LIEES AUX β-AMYLOIDES DANS LA MALADIE D'ALZHEIMER
US20090036538A1 (en) Treatment methods using triaryl methane compounds
US7259170B2 (en) Macrolides containing pharmaceutical compositions
EP3621628A1 (fr) Méthode de traitement de la sclérose en plaques à l'aide de trioxyde d'arsenic
EP1585525B1 (fr) Utilisation de thiazolobenzoheterocycles pour traiter la sclerose en plaques
EP2314291A1 (fr) Utilisation d'une combinaison de tériflunomide et d'acétate de glatiramère pour le traitement de la sclérose en plaques
AU2002346859A1 (en) Macrolides containing pharmaceutical compositions
CA2400236C (fr) Derives d'indoloquinoxaline entrant dans la preparation d'un medicament de traitement de la sclerose en plaques
US20120107277A1 (en) Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
WO2001095907A1 (fr) Composition pharmaceutique pour le traitement de la sclerose en plaques
WO2011049792A1 (fr) Utilisation de l'association du tériflunomide et de l'acétate de glatiramère pour traiter la sclérose en plaques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1381356

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/16 20060101ALI20080711BHEP

Ipc: A61K 31/52 20060101ALI20080711BHEP

Ipc: A61K 31/167 20060101ALI20080711BHEP

Ipc: A61K 38/21 20060101ALI20080711BHEP

Ipc: A61K 31/675 20060101ALI20080711BHEP

Ipc: A61K 31/519 20060101ALI20080711BHEP

Ipc: A61K 38/13 20060101ALI20080711BHEP

Ipc: A61K 31/573 20060101ALI20080711BHEP

Ipc: C07D 475/08 20060101ALI20080711BHEP

Ipc: A61K 45/06 20060101ALI20080711BHEP

Ipc: A61P 25/00 20060101ALI20080711BHEP

Ipc: A61K 31/165 20060101AFI20080429BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WETTSTEIN, JOSEPH

PUAF Information related to the publication of a search report (a3 document) modified or deleted

Free format text: ORIGINAL CODE: 0009199SEPU

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

D17D Deferred search report published (deleted)
AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20090422

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AXX Extension fees paid

Extension state: MK

Payment date: 20090422

Extension state: AL

Payment date: 20090422

Extension state: SI

Payment date: 20090422

Extension state: LT

Payment date: 20090422

Extension state: RO

Payment date: 20090422

Extension state: LV

Payment date: 20090422

17Q First examination report despatched

Effective date: 20090624

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20170207